The Dudley Group NHS
NHS Foundation Trust

Trust Headquarters
Russells Hall Hospital
Dudley
West Midlands
DY1 2HQ

FREEDOM OF INFORMATION ACT 2000 - Ref: FOI/011112

With reference to your FOI request that was received on 02/04/2012 in connection with 'Cancer'.

Your request for information has now been considered and the information requested is attached.

Further information about your rights is also available from the Information Commissioner at:

Information Commissioner
Wycliffe House
Water Lane
Wilmslow
Cheshire SK9 5AF
Tel: 0303 123 1113
Fax: 01625 524510
www.ico.gov.uk

Yours sincerely

Information Governance Manager
Room 34a, First Floor, Esk House, Russells Hall Hospital, Dudley, DY1 2HQ
Email: FOI@dgh.nhs.uk

THE DUDLEY GROUP NHS FOUNDATION TRUST

Rarer Cancers Foundation: Cancer Drugs Fund Freedom of Information requests FOI 011112

1. Please confirm or deny whether your trust has submitted applications for cancer drugs using the Cancer Drugs Fund between April 2011 and February 2012 inclusive.

   Trust confirms application submissions to CDF between the timelines

2. Please supply the number of applications that your trust has submitted for cancer drugs using the Cancer Drugs Fund between April 2011 and February 2012 inclusive, broken down by cancer treatment and indication.

Agent(s)	**Disease**
Lapatinib (with Capecitabine)	Metastatic Breast
Everolimus	Metastatic Renal Cell
Lapatinib (with Capecitabine)	Metastatic Breast
Lapatinib (with Capecitabine)	Metastatic Breast
Lapatinib (with Capecitabine)	Metastatic Breast
Bevacizumab (+IrMdG)	Colorectal Cancer
Panitumumab	Met Colorectal Cancer
Panitumumab	Met Colorectal Cancer
FolFOX = Oxaliplatin+5FU	**Pancreatic**
Panitumumab	Met Colorectal Cancer
Bevacizumab (+IrMdG)	Colorectal Cancer
Bevacizumab (+IrMdG)	Colorectal Cancer
Bevacizumab (+IrMdG)	Colorectal Cancer
Bevacizumab (Raltetrexed + Irinotecan)	Colorectal Cancer
Bevacizumab (+IrMdG)	Colorectal Cancer
Bevacizumab (+IrMdG)	Colorectal Cancer
Bevacizumab (+IrMdG)	Colorectal Cancer
Bevacizumab (+IrMdG)	Colorectal Cancer
FolFOX = Oxaliplatin+5FU	Pancreatic

Rituximab	Folicular Lymph
Bevacizumab (+IrMdG)	Colorectal Cancer
Sorafenib	Hepatocellular
Sorafenib	Hepatocellular
Sorafenib	Hepatocellular
Panitumumab	Colorectal Cancer
Everolimus	NeuroEndoTum
Fulvestrant HD (Faslodex)	Breast
Paclitaxel Albumin (Abraxane)	Metastatic Breast
Bevacizumab (+IrMdG)	Colorectal Cancer
Paclitaxel Albumin (Abraxane)	Metastatic Breast
FolFOX = Oxaliplatin+5FU	Pancreatic
Paclitaxel Albumin (Abraxane)	Metastatic Breast
Fulvestrant HD (Faslodex)	Breast
Fulvestrant HD (Faslodex)	Breast
Bevacizumab (+Paclitaxel)	Metastatic Breast
Bevacizumab (+OxMdG)	Colorectal Cancer
Bevacizumab (+IrMdG)	Colorectal Cancer
~~Bevacizumab (breast)~~	~~Breast~~
Rituximab	Folicular Lymph
Bevacizumab (+IrMdG)	Colorectal Cancer
Bevacizumab (+IrMdG)	Colorectal Cancer
Bevacizumab (+OxMdG)	Colorectal Cancer
Bevacizumab (+IrMdG)	Colorectal Cancer
FolFOX = Oxaliplatin+5FU	Pancreatic
Fulvestrant HD (Faslodex)	Breast

Fulvestrant HD (Faslodex)	Breast
Temsirolimus	mRCC
Temsirolimus	mRCC
Myocet	Metastatic Breast
Panitumumab	CRC
Imatinib	GIST
Bevacizumab (+IrMdG)	Colorectal Cancer
Bevacizumab (+IrMdG)	Colorectal Cancer
Everolimus	Liver NET
Bevacizumab (+IrMdG)	Colorectal Cancer
Bevacizumab (+IrMdG)	Colorectal Cancer
Bevacizumab (+IrMdG)	Colorectal Cancer
Panitumumab	Colorectal Cancer
Paclitaxel Albumin (Abraxane)	Metastatic Breast
Bevacizumab (+IrMdG)	Colorectal Cancer
Bevacizumab (+IrMdG)	Colorectal Cancer
Bevacizumab (+IrMdG)	Colorectal Cancer
Bevacizumab (+OxMdG)	Colorectal Cancer
Bevacizumab (+OxMdG)	Colorectal Cancer
Bevacizumab (+IrMdG)	Colorectal Cancer
Bevacizumab (+OxMdG)	Colorectal Cancer
Bortezomib	Myeloma
Bevacizumab (+OxMdG)	CRC Colorectal Cancer
Abiraterone	Prostate
Abiraterone	Prostate
Paclitaxel Albumin (Abraxane)	Metastatic Breast

Bevacizumab (+OxMdG)	CRC
Cetuximab	Head+Neck
Lapatinib (with Capecitabine)	Metastatic Breast
Bevacizumab (+IrMdG)	Colorectal Cancer
Bevacizumab (+OxMdG)	Colorectal Cancer
FolFOX = Oxaliplatin+5FU	Pancreatic
Bevacizumab (+IrMdG)	**mCRC**
Abiraterone	Prostate
Abiraterone	Prostate
~~Paclitaxel Albumin (Abraxane)~~	~~mBreast~~
Carboplatin+Paclitaxel weekly	**Ovarian**
Bevacizumab (+OxMdG)	Colorectal Cancer
Bevacizumab (+OxMdG)	Colorectal Cancer
Sorafenib	Hepatocellular
Bevacizumab (+OxMdG)	Colorectal Cancer
Abiraterone	Prostate
Cabazitaxel	Prostate
FolFOX = Oxaliplatin+5FU	Pancreatic
Bevacizumab (+OxMdG)	Colorectal Cancer
Panitumumab	Colorectal Cancer
Panitumumab	Colorectal Cancer
Bevacizumab (+OxMdG)	Colorectal Cancer
Fulvestrant HD (Faslodex)	Metastatic Breast
Lapatinib (with Capecitabine)	mBreast
Abiraterone	Prostate
Abiraterone	Prostate

Rituximab	MCLymphoma
Fulvestrant HD (Faslodex)	Metastatic Breast
Abiraterone	Prostate
Bevacizumab (+IrMdG)	Colorectal Cancer
Bevacizumab (+IrMDG)	Colorectal Cancer
Fulvestrant HD (Faslodex)	Metastatic Breast
Abiraterone	Prostate
Abiraterone	Prostate
Ipilimumab	mMelenoma
Everolimus	mRCC
Bevacizumab (+IrMdG)	Colorectal Cancer
Bevacizumab (+OxMdG)	Colorectal Cancer
Bevacizumab (+OxMdG)	Colorectal Cancer
FolFOX = Oxaliplatin+5FU	Pancreatic
Abiraterone	Prostate
Bevacizumab (+OxMdG)	Colorectal Cancer
Bevacizumab (+IrMdG)	Colorectal Cancer
Fulvestrant HD (Faslodex)	Metastatic Breast
Bevacizumab (+OxMdG)	Colorectal Cancer
Bevacizumab (+IrMdG)	Colorectal Cancer
Bevacizumab (+IrMdG)	Colorectal Cancer
Bevacizumab (+IrMdG)	Colorectal Cancer
Bevacizumab (+OxMdG)	Colorectal Cancer
Bevacizumab (+OxMdG)	Colorectal Cancer
Bevacizumab (+OxMdG)	Colorectal Cancer
Panitumumab	Colorectal Cancer

Fulvestrant HD (Faslodex)	Metastatic Breast
Abiraterone	Prostate
Abiraterone	Prostate
Abiraterone	Prostate
Eribulin	mBreast
Alemtuzumab	**PWCA**
Abiraterone	Prostate
Bevacizumab (+IrMdG)	Colorectal Cancer
Panitumumab	Colorectal Cancer
Bevacizumab (+OxMdG)	Colorectal Cancer
Eribulin	Metastatic Breast
Bevacizumab (+OxMdG)	Colorectal Cancer
Bevacizumab (+OxMdG)	Colorectal Cancer
Bevacizumab (+IrMdG)	Colorectal Cancer
Cetuximab	Colorectal Cancer
Paclitaxel Albumin (Abraxane)	Metastatic Breast
Bevacizumab (+IrMdG)	Colorectal Cancer
Bevacizumab (+OxMdG)	Colorectal Cancer
Fulvestrant HD (Faslodex)	Breast
Paclitaxel Albumin (Abraxane)	Breast
Panitumumab	Colorectal Cancer
Cetuximab	Head+Neck
Bevacizumab (+OxMdG)	Colorectal Cancer
Bevacizumab (+IrMdG)	Colorectal Cancer
Bevacizumab (+IrMdG)	Colorectal Cancer
FolFOX = Oxaliplatin+5FU	Pancreatic

Bevacizumab (+OxMdG)	CRC Colorectal Cancer
Fulvestrant HD (Faslodex)	Metastatic Breast
Panitumumab	Colorectal Cancer
Vemurafenib	Melenoma
Bevacizumab (+IrMdG)	Colorectal Cancer
Panitumumab	Colorectal Cancer
Panitumumab	Colorectal Cancer
Bevacizumab (+OxMdG)	Colorectal Cancer
Bevacizumab (+IrMdG)	Colorectal Cancer
FolFOX = Oxaliplatin+5FU	Pancreatic

Key:

Cross through = approved applications but patient did not receive treatment e.g. became progressively unwell etc

Red = individual funding from either the PCT or CDF process (all others are cohort policies)

Highlighted = applications rejected by CDF / PCT process

3. Please confirm or deny whether your trust has submitted applications for cancer drugs to be used outside of their licensed indication (off-label) using the Cancer Drugs Fund between April 2011 and February 2012 inclusive.

   Trust can confirm the use of off-label use of drugs that have been approved knowingly by CDF panel either as cohort policies or as individual funding requests.